Cargando…

Safety and immunogenicity of human papillomavirus vaccination in juvenile patients with rheumatic diseases

Detalles Bibliográficos
Autores principales:	Heijstek, MW, Groot, N, Scherpenisse, M, Tacke, C, Berbers, G, van der Klis, F, Wulffraat, NM
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194438/ http://dx.doi.org/10.1186/1546-0096-9-S1-O41

Ejemplares similares

Measles, Mumps, Rubella serology in juvenile idiopathic arthritis
por: Heijstek, MW, et al.
Publicado: (2008)

Single-nucleotide polymorphisms in the folate pathway are associated with response to methotrexate treatment in juvenile idiopathic arthritis
por: Heijstek, MW, et al.
Publicado: (2008)

Validation of the juvenile artritis disease activity score in 1124 patient visits
por: de Vries, LD, et al.
Publicado: (2011)

Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis
por: Van Dijkhuizen, Pieter E H, et al.
Publicado: (2011)

PReS-FINAL-2181: Recombinant il-1ra restores the il-18-nk cell axis in steroid naive systemic juvenile idiopathic arthritis
por: De Jager, W, et al.
Publicado: (2013)

Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study
por: Grein, Ingrid Herta Rotstein, et al.
Publicado: (2020)

4.5 Defective phosphorylation of the interleukin 18 receptor beta-chain causes impaired NK cell function in systemic onset Juvenile Idiopathic Arthritis
por: de Jager, W, et al.
Publicado: (2008)

Etanercept in juvenile idiopathic arthritis: Who will benefit?
por: Otten, MH, et al.
Publicado: (2011)

Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase III study
por: Ruperto, N, et al.
Publicado: (2011)

SHARE – workpackage 5: development of best practices of diagnosis and treatment for paediatric rheumatic diseases throughout Europe
por: Vastert, Sebastiaan, et al.
Publicado: (2014)

Long term efficacy and safety of canakinumab in children with systemic juvenile idiopathic arthritis with and without fever
por: Horneff, G, et al.
Publicado: (2015)

Efficacy, Immunogenicity and Safety of Vaccination in Pediatric Patients With Autoimmune Inflammatory Rheumatic Diseases (pedAIIRD): A Systematic Literature Review for the 2021 Update of the EULAR/PRES Recommendations
por: Jansen, Marc H., et al.
Publicado: (2022)

Treatment of methotrexate (MTX) intolerance: behavioural therapy, versus switch to parenteral MTX versus oral MTX
por: Verkaaik, M, et al.
Publicado: (2011)

Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis
por: Van Dijkhuizen, EH Pieter, et al.
Publicado: (2011)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
por: De Benedetti, Fabrizio, et al.
Publicado: (2012)

PReS-FINAL-2147: Immunological consequences of biologicals in juvenile idiopathic arthritis
por: Swart, JF, et al.
Publicado: (2013)

2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)
por: Ruperto, N, et al.
Publicado: (2008)

Improving the immunogenicity of HIV-1 envelope trimer vaccines
por: Sanders, Rogier W
Publicado: (2011)

Vaccinations in Paediatric Rheumatology: an Update on Current Developments
por: Groot, Noortje, et al.
Publicado: (2015)

Akinra restores the defective IL-18 NK cell axis in steroid naïve systemic onset JIA patients
por: de Jager, W, et al.
Publicado: (2011)

Recombinant IL1-RA in the early phase of systemic onset JIA: before the onset of arthritis
por: Vastert, SJ, et al.
Publicado: (2011)

Yellow fever vaccination in Brazil: Short-term safety and immunogenicity in juvenile autoimmune rheumatic diseases
por: Emi Aikawa, Nádia, et al.
Publicado: (2021)

Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles
por: Goepfert, P, et al.
Publicado: (2012)

2.5 Mesenchymal Stem Cell Therapy has significant clinical effect in proteoglycan induced arthritis
por: Swart, JF, et al.
Publicado: (2008)

Tapering and withdrawal of tocilizumab in patients with systemic juvenile idiopathic arthritis in inactive disease: results from an alternative dosing regimen in the TENDER study
por: De Benedetti, F, et al.
Publicado: (2014)

PReS-FINAL-2177: Safety and lack of autoantibody production following influenza H1N1 vaccination in patients with juvenile idiopathic arthritis (JIA)
por: Aikawa, N, et al.
Publicado: (2013)

First-in-human phase 1 trial of the safety and immunogenicity of a recombinant adenovirus serotype 5 HVR48 (rAd5HVR48) HIV-1 vaccine
por: Walsh, SR, et al.
Publicado: (2012)

Increased immunogenicity of HIV vaccination with constant-current electroporation and molecular adjuvants in mice and rhesus macaques
por: Hirao, Lauren, et al.
Publicado: (2006)

Long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis
por: Ruperto, N, et al.
Publicado: (2011)

Safety and efficacy of ultrasound guided corticosteroid injections into temporomandibular joints in children with active juvenile idiopathic arthritis
por: Habibi, S, et al.
Publicado: (2011)

Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations
por: Rondaan, Christien, et al.
Publicado: (2019)

Immunologic reactants in the pathogenesis of atherosclerosis in rheumatic diseases
por: Cronstein, B, et al.
Publicado: (2003)

Future direction of pathogenesis and treatment for rheumatic disorders
por: Gay, Steffen
Publicado: (2012)

Cardiac magnetic resonance in acute rheumatic fever
por: Sepulveda, Diana Lamprea, et al.
Publicado: (2013)

2.1 Long-term safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis (JIA)
por: Yokota, S, et al.
Publicado: (2008)

Development of new classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
por: Minoia, Francesca, et al.
Publicado: (2014)

OA04-01. Safety and immunogenicity of LIPO-5, a HIV-1 lipopeptide vaccine: results of ANRS VAC18, a phase 2, randomized, double-blind, placebo-controlled trial
por: Salmon-Céron, D, et al.
Publicado: (2009)

3.5 Comparison of functional ability in juvenile idiopathic arthritis, juvenile dermatomyositis, juvenile systemic lupus erythematosus and healthy controls. An analysis of the PRINTO database
por: Filocamo, G, et al.
Publicado: (2008)

Characteristics of HPV-Specific Antibody Responses Induced by Infection and Vaccination: Cross-Reactivity, Neutralizing Activity, Avidity and IgG Subclasses
por: Scherpenisse, Mirte, et al.
Publicado: (2013)

From rheumatic diseases to cancer - role of autoantibodies as diagnostic biomarkers
por: Tan, Eng M
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_a591kravo018r270sim3lc6t4f